ClinicalTrials.gg
Status unknownNCT03603951Updated Oct 1, 2024

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

A Phase 1 interventional study of SHR2554 in Relapsed or Refractory Mature Lymphoid Neoplasms, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-01.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2024), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
272
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554.

This study will assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in participants with relapsed or refractory mature lymphoid neoplasms in part I, and the the efficacy in PTCL patients will be studied in Part II.

02

Conditions studied

  • Relapsed or Refractory Mature Lymphoid Neoplasms

Browse trials for

Keywords

  • SHR2554
  • EZH2 inhibitor
  • phase 1
  • mature lymphoid neoplasm
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 70 years old (Adult, Senior)
  2. Part I: or cytologically confirmed Mature lymphoid neoplasms; Part II: peripheral T cell lymphomas
  3. (ECOG) performance status of 0 or 1;
  4. Has a of ≥12 weeks;
  5. Resistant to standard therapy or no standard therapy available,have indications for treatment;
  6. Have (lymphoma participants,any nodes/nodal masses>1.5 cm in longest diameter (LDi) or extralymphatic sites of disease >1.0 cm in LDi;Multiple myeloma (MM) or Waldenström macroglobulinemia (WM) participants,serum M protein ≥0.5 g/dL or Bence Jones protein≥0.2 g/24 h). (dose expansion study must satisfy)
  7. Has sufficient tumor tissue (slides or blocks) available for testing EZH2 mutation status and expression level. (dose expansion study must satisfy)
  8. Diffuse large B-cell lymphoma (DLBCL) participants have immunohistochemistry test results of cell origin (germinal center B-cell-like (GCB) or non-GCB), as well as myelocytomatosis oncogene (MYC), B cell lymphoma/leukemia 2 (BCL2) and B-cell lymphoma 6 (BCL6), or provide sufficient tumor tissue for testing. (dose expansion study must satisfy)
  9. With adequate bone marrow function;
  10. With adequate renal and liver function;
  11. Coagulation function index:PT ≤1.5×, ≤1.5×ULN;
  12. Women of (WOCBP) should be proven to be negative by human chorionic gonadotropin (hCG) test in 7 days before the first dose of SHR2554. They must be willing and able to employ a highly effective method of /contraception to prevent pregnancy from the day they sign the form (ICF) to at least 30 days after receiving the last dose of study treatment. Male subjects with WOCBP partner should receive Surgical sterilization or consent to employ a highly effective method of birth control/contraception to prevent pregnancy;
  13. Any prior treatment-related toxicities have resolved to ≤ Grade 1 per version 4.03 or prior treatment-related toxicities evaluated by physicians are not clinically significant at time of enrollment.
  14. Participant who has provided written consent to participate in the study and ability to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to other inhibitor(s) of EZH2.
  2. FL 3b or (potentially) transformed FL
  3. Participants with a presence of central nerves invasion
  4. Auto-transplantation within 60 days or allo-transplantation within 90 days before the first dose of study drug; >1 grade (GVHD) or using GVHD control medicines that are not allowed by this trial;
  5. Major surgery or serious trauma within 4 weeks before the first dose of study drug.;
  6. anti-tumor agents within 4 weeks before the first dose of study drug(such as chemotherapy, radiotherapy, immunotherapy, target therapy and other clinical research);Use of Chinese Herbal within 2 weeks before the first dose of study drug;use of to anti tumor within 7 days before the first dose of study drug(equivalent to prednisone>20 mg/d);
  7. Has known active infection with virus or virus(HBV DNA≥2×10\^3 IU/mL,HCV RNA≥10\^3 IU/mL)and liver dysfunction,need the intervention of anti-virus therapy;
  8. (i.e. has congenital immunodeficiency), including subjects known history of infection with (HIV) or has known active infection with tubercle bacillus;
  9. Has an active infection or has a temperature > 38.5°C with unknown reasons(Investigators will decide the enrollment of participants with a fever that contributed to tumors);
  10. Has cardiovascular impairment,including history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 1 year prior to the planned first dose of study drug; or ventricular cardiac arrhythmia requiring medical treatment;
  11. abnormal of with clinical significance:such as prolongation of interval using Fridericia's formula (QTcF)(male > 450 ms、female> 470 ms);
  12. History of cerebrovascular accident or within 6 months;
  13. Has a prior other than the malignancies under study within 2 years- EXCEPTION: A subject with a history of a completely resected skin basal cell carcinoma, skin squamous-celled carcinoma, in situ cervical cancer or other in situ carcinomas, and has been relapse-free for 5 years;
  14. Has serious acute/chronic disease or psychic disease,such as suicide intention or action in resent 1 year; or there are abnormal conditions that will increase the risk of using or managing study drug or affect the assessment of study results or investigator's judgment;
  15. Staffs of institute sites directly related to the study or their family members, subordinates. Staffs of the sponsor pharmaceuticals company that directly related to the study;
  16. Females who are pregnant or breastfeeding.
  17. Inability to take oral medication, or any uncontrolled gastrointestinal condition (e.g., active gastroenteritis, chronic diarrhea, known diverticulosis, history of gastrectomy or gastric banding) that might impair the bioavailability of study drug. gastroesophageal reflux disease treated with proton pump inhibitors is eligible(should be no drug interaction);
  18. Use of known median or potent or CYP3A5 inducers/inhibitors or P-gp inhibitors.
  19. Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    SHR2554 treated group

    Part I:treated with escalated doses of EZH2 inhibitor SHR2554 respectively; Part II:treated with fixed dose (RP2D) SHR2554 respectively

    Drug: SHR2554

Interventions

  • SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.

    Also known as: EZH2 Inhibitor

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability])(Part I)

    The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of SHR2554 will be assessed.

    Time frame: through study completion, an average of about 6 months

  2. Recommended phase 2 dose (RP2D)(Part I)

    Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) will be established according to the incidence of dose-limiting toxicities (DLTs) of escalated doses of SHR2554.

    Time frame: 30 days since the date of first dose

  3. Objective response rate (ORR)(Part II)

    assessed by independent radiology review committee (IRC)

    Time frame: 60 days since the date of first dose

Secondary outcomes

  1. Time to peak (Tmax)

    Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Time to peak (Tmax) of plasma concentration

    Time frame: Day 1 and Day 2 of the single dose

  2. Maximum plasma concentration (Cmax)

    Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Maximum plasma concentration (Cmax)

    Time frame: Day 1 and Day 2 of the single dose

  3. Halflife (T1/2)

    Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Halflife (T1/2)

    Time frame: Day 1 and Day 2 of the single dose

  4. Clearance/ bioavailability (CL/F)

    Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Clearance/ bioavailability (CL/F)

    Time frame: Day 1 and Day 2 of the single dose

  5. apparent volume of distribution/bioavailability (Vd/F)

    Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): apparent volume of distribution/bioavailability (Vd/F)

    Time frame: Day 1 and Day 2 of the single dose

  6. Area under curve (AUC)

    Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Area under curve (AUC)

    Time frame: Day 1 and Day 2 of the single dose

  7. Area under curve, steady state (AUCss)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Area under curve, steady state (AUCss)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  8. Maximum plasma concentration, steady state (Cmax,ss)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Maximum plasma concentration, steady state (Cmax,ss)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  9. Time to peak, steady state (Tmax,ss)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Time to peak, steady state (Tmax,ss)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  10. Halflife (T1/2)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Halflife (T1/2)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  11. Apparent volume of distribution, steady state/bioavailability (Vss/F)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Apparent volume of distribution, steady state/bioavailability (Vss/F)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  12. Clearance/ bioavailability (CL/F)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Clearance/ bioavailability (CL/F)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  13. Accumulation index (Rac)

    Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Accumulation index (Rac)

    Time frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)

  14. Objective response rate (ORR)

    Assess the response rate of subjects to the treatment of SHR2554

    Time frame: every 8 weeks through study completion, an average of about 6 months

  15. Progression-free survival (PFS)

    Assess the survival condition of the subjects after the treatment of SHR2554

    Time frame: every 8 weeks through study completion, an average of about 6 months

  16. Duration of Response (DoR)

    Assess the duration of complete/partial response after the treatment of SHR2554

    Time frame: every 8 weeks through study completion, an average of about 6 months

  17. Time to response(TTR)(Part II only)

    Assess the time to initial response of subjects to the treatment of SHR2554

    Time frame: 60 days since the date of first dose

  18. OS(overall survival)(Part II only)

    Assess the overall survival of subjects treated by SHR2554

    Time frame: 2 years since the date of first dose

Other outcomes

  1. Effect of escalated doses of SHR2554 on the histone H3 lysine 27 trimethylation (H3K27me3) level(Part I-exploratory endpoints)

    Analyze the level of H3K27me3 in the peripheral blood mononuclear cells of the subjects before and after the treatment of escalated doses of SHR2554.

    Time frame: day 1 of the single dose to day 1 of continuous medication cycle 2

  2. EZH2 gene mutation(Part I-exploratory endpoints)

    Assess the known mutation of EZH2 gene in tumor cells or tissues, analyze the relationship between efficacy and EZH2 mutation

    Time frame: within 2 weeks after the last dose

  3. EZH2 expression level(Part I-exploratory endpoints)

    Assess EZH2 expression level in tumor tissues, analyze the relationship between efficacy and EZH2 expression level

    Time frame: within 2 weeks after the last dose

07

Study locations

1 site
  • Beijing Cancer Hospital, Peking University
    Beijing, Beijing Municipality, China
08

References and documents

Publications

  • Song Y, Jin Z, Li ZM, Liu Y, Li L, He C, Su H, Zhou H, Li K, Hao S, Zuo X, Wu J, Li D, Wu M, Sun X, Qi J, Cai Z, Li Z, Li Y, Huang Y, Shen J, Xiao Z, Zhu J. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study. Clin Cancer Res. 2024 Apr 1;30(7):1248-1255. doi: 10.1158/1078-0432.CCR-23-2582. PubMed 38190117 ↗
  • Song Y, Liu Y, Li ZM, Li L, Su H, Jin Z, Zuo X, Wu J, Zhou H, Li K, He C, Zhou J, Qi J, Hao S, Cai Z, Li Y, Wang W, Zhang X, Zou J, Zhu J. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 2022 Jul;9(7):e493-e503. doi: 10.1016/S2352-3026(22)00134-X. PubMed 35772429 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2018 (actual). Primary completion is estimated for Feb 2026, 90 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 27, 2018
StartActual
Aug 14, 2018
Primary completionEst.
Feb 14, 2026
CompletionEst.
Aug 14, 2026
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03603951
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Aug 14, 2018
Primary completion
Feb 14, 2026 (estimated)
Completion
Aug 14, 2026 (estimated)
Last update
Oct 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion